IMM initiatesIND-Enabling Program for Kapiglucagon

AI SummaryClose X

ImmuPharma PLC has initiated IND-enabling activities for its Kapiglucagon diabetes program, a proprietary glucagon prodrug for Type 1 diabetes, by engaging tranScrip Limited to develop the regulatory strategy and prepare for a pre-IND meeting with the FDA. The company plans to utilize a 505(b)(2) regulatory pathway in the United States, leveraging existing data on native glucagon, with the goal of improving solubility and formulation stability for next-generation artificial pancreas systems. This program is supported by recently approved funding intended to advance the asset over the next two years, with a projected global insulin pump market reaching $13.6 billion in sales by 2035.

Disclaimer*

Companies

Immupharma (IMM)
UK 100

Latest directors dealings